STAAR Surgical (NASDAQ:STAA) Major Shareholder Purchases $387,419.94 in Stock

STAAR Surgical (NASDAQ:STAA - Get Free Report) major shareholder Broadwood Partners, L.P. purchased 22,189 shares of the business's stock in a transaction that occurred on Monday, March 31st. The shares were purchased at an average price of $17.46 per share, for a total transaction of $387,419.94. Following the completion of the acquisition, the insider now owns 12,455,264 shares of the company's stock, valued at $217,468,909.44. The trade was a 0.18 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Monday, April 7th, Broadwood Partners, L.P. bought 138,054 shares of STAAR Surgical stock. The stock was acquired at an average cost of $15.61 per share, with a total value of $2,155,022.94.
• On Friday, April 4th, Broadwood Partners, L.P. purchased 497,631 shares of STAAR Surgical stock. The shares were acquired at an average cost of $15.91 per share, with a total value of $7,917,309.21.
• On Wednesday, April 2nd, Broadwood Partners, L.P. acquired 31,780 shares of STAAR Surgical stock. The stock was acquired at an average cost of $17.43 per share, for a total transaction of $553,925.40.
• On Thursday, March 27th, Broadwood Partners, L.P. bought 3,620 shares of STAAR Surgical stock. The shares were acquired at an average cost of $17.48 per share, with a total value of $63,277.60.
• On Tuesday, March 25th, Broadwood Partners, L.P. purchased 34,296 shares of STAAR Surgical stock. The stock was bought at an average cost of $17.44 per share, for a total transaction of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. acquired 108,720 shares of STAAR Surgical stock. The shares were bought at an average price of $17.96 per share, with a total value of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. bought 93,124 shares of STAAR Surgical stock. The stock was bought at an average price of $17.54 per share, for a total transaction of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. purchased 249,503 shares of STAAR Surgical stock. The shares were bought at an average price of $16.64 per share, with a total value of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. acquired 259,316 shares of STAAR Surgical stock. The stock was purchased at an average price of $17.05 per share, for a total transaction of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. bought 36,532 shares of STAAR Surgical stock. The stock was purchased at an average cost of $15.49 per share, with a total value of $565,880.68.

STAAR Surgical Trading Up 1.4 %

Shares of STAAR Surgical stock traded up $0.22 on Monday, reaching $16.14. The stock had a trading volume of 1,526,031 shares, compared to its average volume of 784,406. The business's 50 day moving average is $18.65 and its two-hundred day moving average is $24.55. STAAR Surgical has a 1 year low of $13.50 and a 1 year high of $52.68. The company has a market cap of $796.11 million, a P/E ratio of -39.37 and a beta of 0.75.

Remove Ads

Analyst Ratings Changes

A number of research analysts have recently commented on STAA shares. Stifel Nicolaus dropped their price target on STAAR Surgical from $38.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, February 12th. BTIG Research downgraded shares of STAAR Surgical from a "buy" rating to a "neutral" rating in a report on Wednesday, February 12th. Stephens reiterated an "equal weight" rating and issued a $17.00 target price on shares of STAAR Surgical in a research note on Tuesday, March 18th. Piper Sandler lowered their price target on shares of STAAR Surgical from $40.00 to $16.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 12th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of STAAR Surgical in a report on Thursday, February 27th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $25.29.

Institutional Trading of STAAR Surgical

Several institutional investors and hedge funds have recently bought and sold shares of STAA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of STAAR Surgical by 3.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,123 shares of the medical instruments supplier's stock worth $683,000 after purchasing an additional 1,044 shares during the period. Quarry LP purchased a new position in STAAR Surgical during the third quarter worth about $50,000. MetLife Investment Management LLC increased its stake in STAAR Surgical by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 30,396 shares of the medical instruments supplier's stock worth $738,000 after acquiring an additional 1,796 shares during the last quarter. Bridgefront Capital LLC increased its stake in STAAR Surgical by 27.2% in the 4th quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier's stock worth $262,000 after acquiring an additional 2,306 shares during the last quarter. Finally, Illinois Municipal Retirement Fund boosted its position in shares of STAAR Surgical by 8.3% during the 4th quarter. Illinois Municipal Retirement Fund now owns 30,144 shares of the medical instruments supplier's stock valued at $732,000 after acquiring an additional 2,318 shares during the last quarter. 96.70% of the stock is currently owned by hedge funds and other institutional investors.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.